SOPH — SOPHiA GENETICS S.A. stock price, charts and financials

NASDAQ·Healthcare·Medical - Healthcare Information Services·Switzerland

Latest market price

5.69

+0.02+0.35%

Overview Short InterestFilings

SOPHQT74SOPHiA GENETICS S.A.·NASDAQ

Overview Short InterestFilings

5.69+0.35%

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CTEV+6.96%$24.29 TBRG+0.00%$26.24 EVH+1.62%$3.14 NRC-0.05%$19.50 PHR+5.31%$11.30 HSTM+1.03%$28.33 GDRX+2.93%$3.16 OMDA+3.38%$20.51

Snapshot

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	11.84%	Shs Outstand	68.74M	Perf Week	-0.87%

Market Cap	389.75M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-6.45%	Shs Float	54.74M	Perf Month	1.43%

Enterprise Value	386.78M	PEG	0.29	EPS next Q	-	Inst Own	-	Short Float	1.21%	Perf Quarter	8.62%

Income	-78.22M	P/S	4.80	EPS this Y	31.36%	Inst Trans	-	Short Ratio	3.31	Perf Half Y	9.67%

Sales	81.18M	P/B	8.83	EPS next Y	30.37%	ROA	-51.55%	Short Interest	661.35K	Perf YTD	21.41%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-140.63%	52W High	6.79 -16.25%	Perf Year	78.30%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-63.43%	52W Low	2.93 94.18%	Perf 3Y	42.11%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	17.06% 22.42%	Gross Margin	67.28%	Volatility	5.38% 6.46%	Perf 5Y	-66.17%

Dividend TTM	-	EV/Sales	4.76	EPS Y/Y TTM	-24.21%	Oper. Margin	-88.39%	ATR (14)	0.38	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	1.90	Sales Y/Y TTM	24.62%	Profit Margin	-99.70%	RSI (14)	49.35	Recom	2.14

Dividend Gr. 3/5Y	-	Current Ratio	2.06	EPS Q/Q	-3.85%	SMA20	-2.10%	Beta	0.93	Target Price	10.00

Payout	0.00%	Debt/Eq	1.37	Sales Q/Q	22.22%	SMA50	4.09%	Rel Volume	0.33	Prev Close	5.67

Employees	415	LT Debt/Eq	1.30	Earnings	Aug 04	SMA200	14.63%	Avg Volume	237.85K	Price	5.69

IPO Date	Jul 23, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-16.13% 6.29%	Net Debt/EBITDA	0.04	Volume	78,332	Change	0.35%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-20-26	Initiated	H.C	Buy	$12
Apr-15-26	Reiterated	BTIG	Buy	$7.00 → $8.00
Mar-03-26	Reiterated	BTIG	Buy	$5.00 → $7.00
Jan-26-26	Reiterated	Guggenheim	Buy	$6.00 → $7.00
Mar-06-25	Reiterated	BTIG	Buy	$6.00 → $5.00
Aug-07-24	Reiterated	Morgan Stanley	Overweight	$5.00
Jun-27-24	Reiterated	Guggenheim		$6.00
Jan-03-23	Reiterated	BTIG	Buy	$6.00

Latest News

Jul-21-26

Jul-21-2608:00AM

SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026prnewswire.com

Jul-20-26

Jul-20-2608:39AM

This Charles Schwab Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For MondayBenzinga

Jun-18-26

Jun-18-2608:22AM

SOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseSeekingAlpha

Jun-17-26

Jun-17-2608:44AM

Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)Benzinga

08:03AM

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga

02:50AM

CarMax, Jabil And 3 Stocks To Watch Heading Into WednesdayBenzinga

Jun-16-26

Jun-16-2604:22PM

SOPHiA GENETICS Commences Ordinary Shares Offering; Terms UndisclosedBenzinga

Jun-15-26

Jun-15-2608:09AM

BTIG Reiterates Buy on Sophia Genetics, Maintains $8 Price TargetBenzinga

Company

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	81	77	65	62	48	40	28	25
Cost of Goods Sold Incl. D&A	27	29	21	19	16	15	11	8
Gross Profit	55	48	44	43	31	25	18	18
Selling, General and Administrative Excl. Other	92	85	76	82	84	70	36	35
Research and Development	37	34	34	37	35	27	19	15
Other Operating Expense	-2	0	1	-1	0	0	0	0
Operating Income	-72	-71	-67	-75	-88	-71	-37	-32
Interest Expense	7	5	2	1	1	1	1	1
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-3	-3	7	-3	1	-1	-3	0
Net Income Before Taxes	-80	-78	-61	-78	-88	-74	-41	-34
Income Taxes	2	1	1	0	0	0	-2	0
Consolidated Net Income	-80	-79	-62	-79	-87	-74	-39	-34
Net Income From Continuing Operations	-80	-79	-62	-79	-87	-74	-39	-34
Net Income	-80	-79	-62	-79	-87	-74	-39	-34
EPS (Recurring)	-1.18	-1.17	-0.95	-1.22	-1.36	-1.33	-0.82	-0.53
EPS (Basic, Before Extraordinaries)	-1.18	-1.17	-0.95	-1.22	-1.36	-1.33	-0.82	-0.53
EPS (Diluted)	-1.18	-1.17	-0.95	-1.22	-1.36	-1.33	-0.82	-0.53
EBITDA	-66	-64	-51	-70	-81	-69	-38	-31
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	4.99	4.12	3.12	4.94	2.75	19.39	—	—
Gross Margin	67.90	62.34	67.69	69.35	64.58	62.50	64.29	72.00
Operating Margin	-88.89	-92.21	-103.08	-120.97	-183.33	-177.50	-132.14	-128.00
Net Margin	-98.77	-102.60	-95.38	-127.42	-181.25	-185.00	-139.29	-136.00
Shares Outstanding	71	68	66	65	64	55	48	64
Market Capitalization	404	318	203	306	132	776	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Menu Philippe	Chief Medical Officer	Jul 27 '26	Sale	5.66	5,000	28,306	223,387	Jul 28
Camblong Jurgi	Executive Chairman	Jul 21 '26	Sale	6.63	20,000	132,654	3,492,822	Jul 22
Camblong Jurgi	Executive Chairman	Jul 20 '26	Sale	6.29	24,381	153,445	3,512,822	Jul 22
Camblong Jurgi	Executive Chairman	Jul 20 '26	Option Exercise	3.16	4,581	14,476	3,517,403	Jul 22
Menu Philippe	Chief Medical Officer	Jul 13 '26	Sale	5.70	5,000	28,505	228,387	Jul 14
Xu Zhenyu	Chief Scientific Officer	Jul 13 '26	Sale	5.70	4,000	22,819	610,887	Jul 14
Camblong Jurgi	Executive Chairman	Jul 10 '26	Sale	5.62	8,500	47,791	3,532,622	Jul 14
Camblong Jurgi	Executive Chairman	Jul 07 '26	Sale	5.28	17,685	93,327	3,541,122	Jul 08
Camblong Jurgi	Executive Chairman	Jul 06 '26	Sale	5.25	22,486	118,164	3,558,807	Jul 07
Menu Philippe	Chief Medical Officer	Jul 06 '26	Sale	5.16	7,393	38,156	233,387	Jul 07
CARDOZA GEORGE	Chief Financial Officer	Jul 06 '26	Sale	5.29	1,592	8,419	309,092	Jul 07
Valente Manuela	Chief People Officer	Jul 06 '26	Sale	5.05	4,241	21,430	210,450	Jul 07
Verma Abhimanyu	Chief Technology Officer	Jul 06 '26	Sale	5.10	5,285	26,957	192,171	Jul 07
Xu Zhenyu	Chief Scientific Officer	Jul 06 '26	Sale	5.17	7,393	38,242	614,887	Jul 07
Muken Ross	Chief Executive Officer	Jul 06 '26	Sale	5.22	9,838	51,354	670,651	Jul 07

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.